Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 12	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 17	JUL 28	CA/CAplus patent coverage enhanced
NEWS 18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20	JUL 28	STN Viewer performance improved
NEWS 21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 24	AUG 15	CAplus currency for Korean patents enhanced
NEWS 25	AUG 25	CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:16:16 ON 04 SEP 2008

=> FIL REG
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:16:43 ON 04 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    3 SEP 2008  HIGHEST RN 1046204-20-9
DICTIONARY FILE UPDATES:   3 SEP 2008  HIGHEST RN 1046204-20-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

[USER ABORT]
C:\Program Files\STNEXP\Queries\10523422\1.str

0 IS NOT A RECOGNIZED COMMAND
```

```
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
0 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
0 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
0 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
0 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
0 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> D
ENTER NAME OF ITEM TO BE DISPLAYED OR (?):EN
'EN' IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> END
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:N

=>
Uploading C:\Program Files\STNEXP\Queries\10523422\1.str
```





chain nodes :
16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
ring/chain nodes :
21
chain bonds :
8-10 13-16 16-17 16-18 18-19 18-20 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 10-11 10-15 11-12 12-13
13-14 13-16 14-15 16-17 16-18 18-19 18-20 20-21

G1:H,Ak

G2:C,N

G3:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:Atom 21:CLASS

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

G2 C,N

G3 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 15:17:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2221 TO ITERATE

90.0% PROCESSED 2000 ITERATIONS 8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 41593 TO 47247
PROJECTED ANSWERS: 8 TO 355

L2 8 SEA SSS SAM L1

=> S L1 FULL
FULL SEARCH INITIATED 15:17:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 43593 TO ITERATE

100.0% PROCESSED 43593 ITERATIONS 173 ANSWERS
SEARCH TIME: 00.00.01

L3 173 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 15:17:51 ON 04 SEP 2008

FILE COVERS 1907 - 4 Sep 2008 VOL 149 ISS 10
FILE LAST UPDATED: 3 Sep 2008 (20080903/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> S L3
L4 9 L3

=> D IBIB ABS HITSTR L4 TOT

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1064465 CAPLUS
DOCUMENT NUMBER: 147:385970
TITLE: Novel heterocyclic NF-κB inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Leban, Johann; Schmitt, Harald; Wolf, Kristina; Pegoraro, Stefano; Wuzik, Andreas; Krauss, Rolf
PATENT ASSIGNEE(S): 4SC A.-G., Germany
SOURCE: PCT Int. Appl., 110pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007104557	A2	20070920	WO 2007-EP2265	20070314
WO 2007104557	A3	20080522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US	20060247253	A1	20061102	US 2006-375259	20060315
AU	2006278998	A1	20070215	AU 2006-278998	20060315
CA	2617225	A1	20070215	CA 2006-2617225	20060315
WO	2007016979	A2	20070215	WO 2006-EP2396	20060315
WO	2007016979	A3	20070802		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP	1912982	A2	20080423	EP 2006-707574	20060315

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN	101233119	A	20080730	CN 2006-80027299	20080125
KR	2008031038	A	20080407	KR 2008-702431	20080129
IN	2008DN00806	A	20080704	IN 2008-DN806	20080129
NO	2008001056	A	20080228	NO 2008-1056	20080228

PRIORITY APPLN. INFO.:	US 2006-375259	A	20060315
	WO 2006-EP2396	A	20060315
	US 2004-612794P	P	20040927
	US 2005-192009	A2	20050729
	WO 2005-EP8261	A	20050729

OTHER SOURCE(S): MARPAT 147:385970
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to compds. of the general formula I or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof. Compds. of formula I wherein A is NH and derivs., S or O; R3a is H, OH, SH, NH2, -C(NH)NH2 and derivs., (CH2)1-6 aryl, -(CH2)1-6NH2 and derivs., -C(O)NH2 and derivs., alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, alkoxy, (hydroxy)alkylamino, halo, (hetero)aryl, etc.; R3 is H, C0NH2 and derivs., halo, alkyl, haloalkyl, (hetero)aryl, OH and derivs., SH, NH and derivs., NH2, hydroxyalkylamino, alkylamino, alkoxy, cycloalkyl, etc.; X is NH and derivs., O, or S; Z is N or CH, alkyl, C-CONH and derivs., etc.; t is 0 to 4; r is 0 or 1; Rd is H, halo, C(NH)NH2 and derivs., (CH2)1-6 aryl, (CH2)1-6 amino, etc..; R1 is acyl, CHO, CONH2 and derivs., CO2H and derivs., thioacyl, etc.; R2 is H, alkyl, (hetero)cycloalkyl, haloalkyl, hydroxyalkyl, etc.; R2a is H, OH, SH, NH2, alkyl, cycloalkyl,

hydroxyalkyl, etc.; and their pharmaceutically acceptable salts with acids or bases, prodrugs and stereoisomers thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their NF-κB inhibitory activity (no data).

IT 913822-38-5P 913822-40-9P 913822-41-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic NF-KB inhibitors useful in treatment and prevention of diseases associated with abnormal and hyperproliferation of cells)

RN 913822-38-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-(4-morpholinyl)-N-[4-[5-(trifluoromethyl)-2-benzothiazolyl]phenyl]- (CA INDEX NAME)



RN 913822-40-9 CAPLUS
CN 4-Thiazolecarboxamide, N-[4-(2-benzothiazolyl)-2-fluorophenyl]-2-(4-morpholinyl)- (CA INDEX NAME)



RN 913822-41-0 CAPLUS
CN 4-Thiazolecarboxamide, N-[4-(2-benzothiazolyl)-2-(trifluoromethoxy)phenyl]-2-(4-morpholinyl)- (CA INDEX NAME)



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1150357 CAPLUS

DOCUMENT NUMBER: 145:471514
TITLE: Novel 2-(piperidin-4-yl)thiazole derivatives as NF-κB inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of various diseases
INVENTOR(S): Leban, Johann; Schmitt, Harald; Wolf, Kristina; Pegoraro, Stefano; Wuzik, Andreas
PATENT ASSIGNEE(S): 4 Sc AG, Germany
SOURCE: U.S. Pat. Appl. Publ., 52pp., Cont.-in-part of U.S. Ser. No. 192,009.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060247253	A1	20061102	US 2006-375259	20060315
US 20060069102	A1	20060330	US 2005-192009	20050729
WO 2007104557	A2	20070920	WO 2007-EP2265	20070314
WO 2007104557	A3	20080522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

US 2004-612794P	P	20040927
US 2005-192009	A2	20050729
US 2006-375259	A	20060315
WO 2006-EP2396	A	20060315

OTHER SOURCE(S): MARPAT 145:471514
GI



I



II

AB The invention relates to compds. of the general formula I or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof. Compds. of formula I wherein R1 is H, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl(oxy), (un)substituted (hetero)aryl, and (un)substituted arylalkyl; R2 is NR3R4, (un)substituted piperidine, and (un)substituted piperazine; R3 is alkyl, cycloalkyl, alkoxy, alkylamino, OH, SH, alkylthio, hydroxyalkyl, haloalkyl(oxy) and (hetero)aryl; R4 is alkyl, cycloalkyl, alkoxy, alkylamino, alkylthio, hydroxyalkyl, haloalkyl(oxy) and (hetero)aryl; m and n are independently 0 and 1; X is CO and SO2; and their salts and physiol. functionalized derivs. thereof are claimed. Example compound II was prepared by a multistep procedure (general procedure given). All the invention compds. were evaluated for their NF-κB inhibitory activity. From the assay, it was determined that compound II exhibited 90-100 % inhibition.

IT 913822-38-5P 913822-40-9P 913822-41-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperidinylthiazole derivs. as NF-κB inhibitors and their use in the treatment of various diseases)

RN 913822-38-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-(4-morpholinyl)-N-[4-[5-(trifluoromethyl)-2-benzothiazolyl]phenyl]- (CA INDEX NAME)



RN 913822-40-9 CAPLUS
CN 4-Thiazolecarboxamide, N-[4-(2-benzothiazolyl)-2-fluorophenyl]-2-(4-

morpholinyl)- (CA INDEX NAME)



RN 913822-41-0 CAPLUS
CN 4-Thiazolecarboxamide, N-[4-(2-benzothiazolyl)-2-(trifluoromethoxy)phenyl]-2-(4-morpholinyl)- (CA INDEX NAME)



L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:710810 CAPLUS
DOCUMENT NUMBER: 145:159773
TITLE: Benzimidazole derivative transcription factor-modulating compounds for use as antiinfective agents
INVENTOR(S): Alekshun, Michael N.; Amoo, Victor; Kim, Oak K.; Verma, Atul K.
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 405 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006076009	A2	20060720	WO 2005-US14345	20050425
WO 2006076009	A3	20071227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2005324492	A1	20060720	AU 2005-324492	20050425
CA 2562763	A1	20060720	CA 2005-2562763	20050425
US 20060160799	A1	20060720	US 2005-115024	20050425
EP 1742637	A2	20070117	EP 2005-856651	20050425
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2008504233	T	20080214	JP 2007-509742	20050425

PRIORITY APPLN. INFO.:
US 2004-565047P P 20040423
US 2004-569032P P 20040507
US 2004-623251P P 20041028
WO 2005-US14345 W 20050425

OTHER SOURCE(S): MARPAT 145:159773

AB The invention provides substituted benzimidazole compds. useful as antiinfectives that decrease resistance, virulence, or growth of microbes. Also provided are methods for making and using the substituted benzimidazole compds., as well as pharmaceutical prepns. for e.g. reducing antibiotic resistance and inhibiting biofilms.

IT 900142-12-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazole derivative transcription factor-modulating compds. for use as antiinfective agents)

RN 900142-12-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(1-hydroxy-6-nitro-1H-benzimidazol-2-yl)phenyl]-6-(4-morpholinyl)- (CA INDEX NAME)



L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300252 CAPLUS
DOCUMENT NUMBER: 142:373830
TITLE: Preparation of benzimidazoles and imidazopyridines as heparanase inhibitors
INVENTOR(S): Liu, Hu; Miao, Hua-quan
PATENT ASSIGNEE(S): Imclone Systems, Inc., USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005030206 A1 20050407 WO 2004-US31689 20040924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2003-505136P P 20030924
OTHER SOURCE(S): CASREACT 142:373830; MARPAT 142:373830
GI



I



II

AB Title compds. I [wherein Z = N or CH (at least one Z is CH); m, n, p = 0-4; R1, R3 = halo, nitro, amino, cyano, hydroxy, (un)substituted alk(en/yn)l, alkoxy, (hetero)aryl or -NHC(O)-aryl; R2 = H, (un)substituted carbonyl or sulfonyl], which are inhibitors of heparanases and are useful in inhibiting the release of bioactive agents from heparan sulfate proteoglycans, were prepared For example, cyclocondensation of 1,2-phenylenediamine with 3-aminobenzoic acid in the presence of polyphosphoric acid (52% yield) followed by acylation with 3-bromo-4-methoxybenzoyl chloride, which was obtained by chlorination of the corresponding acid with oxalyl chloride, gave amide II (8% yield). Most I showed 29-109% inhibition at the concentration of 25 μM (65% inhibition for II) in the heparanase activity assays.

IT 849509-40-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of benzimidazoles and imidazopyridines as heparanase inhibitors)
RN 849509-40-6 CAPLUS
CN 4-Thiazolecarboxamide, N-[4-(1H-benzimidazol-2-yl)phenyl]-2-[(3-bromo-4-ethoxybenzoyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:120723 CAPLUS
DOCUMENT NUMBER: 140:163697
TITLE: Preparation of biaryl amides with antimicrobial activity
INVENTOR(S): Burli, Roland W.; Baird, Eldon E.; Kaizerman, Jacob A.; McMinn, Dustin L.
PATENT ASSIGNEE(S): Genesoft Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

INSTANT APPLICATION

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004012736	A1	20040212	WO 2003-US24294		20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2494139	A1	20040212	CA 2003-2494139		20030801
AU 2003258022	A1	20040223	AU 2003-258022		20030801
EP 1539151	A1	20050615	EP 2003-767125		20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 20060128747	A1	20060615	US 2005-523422		20051006
PRIORITY APPLN. INFO.:			US 2002-400671P	P	20020802
			WO 2003-US24294	W	20030801

OTHER SOURCE(S): MARPAT 140:163697
GI



I



II

AB The title compds. I [Z = N or (substituted)carbon, with the proviso that no more than 2 Zs in any aromatic ring are N; Y = O, N, or S; Q = N or (substituted)carbon, with the proviso that Q = (substituted)carbon when Y = N; Ar = (substituted)(hetero)aromatic 5- or 6-membered ring; R1 = H, (hetero)alkyl or the two R1 form a (substituted)hetero 5-7 membered ring; R2 = H or alkyl] were prepared as antimicrobial agents. Thus, reaction of N-[4-(2-benzofuranyl)phenyl]-4,5-dichloro-isothiazole-3-carboxamide (preparation given) with 1-piperazineethanamine gave compound II. The latter inhibits Bacillus cereus, Enterococcus faecalis, and Streptococcus aureus with MICs ≤ 4 μg/mL in vitro.

IT 654056-02-7P 654056-03-8P 654056-04-9P
654056-05-0P 654056-06-1P 654056-07-2P
654056-08-3P 654056-09-4P 654056-10-7P
654056-11-8P 654056-12-9P 654056-13-0P
654056-14-1P 654056-15-2P 654056-16-3P
654056-17-4P 654056-18-5P 654056-19-6P
654056-20-9P 654056-21-0P 654056-22-1P
654056-23-2P 654056-28-7P 654056-29-8P
654056-30-1P 654056-31-2P 654056-32-3P
654056-33-4P 654056-34-5P 654056-35-6P
654056-36-7P 654056-37-8P 654056-38-9P
654056-39-0P 654056-40-3P 654056-41-4P
654056-47-0P 654056-48-1P 654056-49-2P
654056-50-5P 654056-51-6P 654056-52-7P
654056-53-8P 654056-54-9P 654056-55-0P
654056-56-1P 654056-57-2P 654056-58-3P
654056-59-4P 654056-60-7P 654056-61-8P
654056-62-9P 654056-63-0P 654056-64-1P
654056-65-2P 654056-66-3P 654056-67-4P

654056-68-5P 654056-69-6P 654056-70-9P
654056-71-0P 654056-72-1P 654056-73-2P
654056-74-3P 654056-75-4P 654056-76-5P
654056-77-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl amides with antimicrobial activity)

RN 654056-02-7 CAPLUS
CN 3-Isothiazolecarboxamide, N-[4-(2-benzofuranyl)phenyl]-4-chloro-5-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-03-8 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(3-aminopropyl)amino]-N-[4-(2-benzofuranyl)phenyl]-4-chloro- (CA INDEX NAME)



RN 654056-04-9 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(2-aminoethyl)amino]-N-[4-(2-benzofuranyl)phenyl]-4-chloro- (CA INDEX NAME)



RN 654056-05-0 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(4-aminobutyl)amino]-N-[4-(2-benzofuranyl)phenyl]-4-chloro- (CA INDEX NAME)



RN 654056-06-1 CAPLUS
CN 3-Isothiazolecarboxamide, N-[4-(2-benzofuranyl)phenyl]-4-chloro-5-[[3-(diethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-07-2 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[[2-[2-(2-aminoethoxy)ethoxy]ethyl]amino]-N-[4-(2-benzofuranyl)phenyl]-4-chloro- (CA INDEX NAME)

PAGE 1-A



RN 654056-08-3 CAPLUS
CN 3-Isothiazolecarboxamide, N-[4-(2-benzofuranyl)phenyl]-4-chloro-5-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-09-4 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[[3-[(3-aminopropyl)methylamino]propyl]amino]-N-[4-(2-benzofuranyl)phenyl]-4-chloro- (CA INDEX NAME)



RN 654056-10-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(3-aminopropyl)amino]-N-[4-(2-benzofuranyl)phenyl]- (CA INDEX NAME)



RN 654056-11-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-12-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-13-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-[[3-(cyclohexylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-14-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-[[2-(1-piperidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-15-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-[[2-(4-thiomorpholinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-16-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-[[2-(1-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-17-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)



RN 654056-18-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[4-(2-aminoethyl)-1-piperazinyl]-N-[4-(2-benzofuranyl)phenyl]- (CA INDEX NAME)



RN 654056-19-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-aminobutyl)amino]-N-[4-(2-benzofuranyl)phenyl]- (CA INDEX NAME)



RN 654056-20-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2-aminoethyl)amino]-N-[4-(2-benzofuranyl)phenyl]- (CA INDEX NAME)



RN 654056-21-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-(1-piperazinyl)- (CA INDEX NAME)



RN 654056-22-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)phenyl]-2-[[2-(diethylamino)ethyl]amino]- (CA INDEX NAME)



RN 654056-23-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[2-[2-(2-aminoethoxy)ethoxy]ethyl]amino]-N-[4-(2-benzofuranyl)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 654056-28-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)-3-methylphenyl]-2-[[2-(1-piperidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-29-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)-3-methylphenyl]-2-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-30-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-aminobutyl)amino]-N-[4-(2-benzofuranyl)-3-methylphenyl]- (CA INDEX NAME)



RN 654056-31-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(2-benzofuranyl)-3-methylphenyl]-2-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-32-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[3-[(3-aminopropyl)methylamino]propyl]amino]-N-[4-(2-benzofuranyl)-3-methylphenyl]- (CA INDEX NAME)



RN 654056-33-4 CAPLUS
CN 3-Isothiazolecarboxamide, N-[4-(2-benzofuranyl)-3-methylphenyl]-4-chloro-5-[[2-(1-piperidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-34-5 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(4-aminobutyl)amino]-N-[4-(2-benzofuranyl)-3-methylphenyl]-4-chloro- (CA INDEX NAME)



RN 654056-35-6 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(3-aminopropyl)amino]-N-[4-(2-benzofuranyl)-3-methylphenyl]-4-chloro- (CA INDEX NAME)



RN 654056-36-7 CAPLUS
CN 3-Isothiazolecarboxamide, N-[6-(2-benzofuranyl)-3-pyridinyl]-4-chloro-5-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-37-8 CAPLUS
CN 3-Isothiazolecarboxamide, N-[6-(2-benzofuranyl)-3-pyridinyl]-4-chloro-5-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-38-9 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(4-aminobutyl)amino]-N-[6-(2-benzofuranyl)-3-pyridinyl]-4-chloro- (CA INDEX NAME)



RN 654056-39-0 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(2-aminoethyl)amino]-N-[6-(2-benzofuranyl)-3-pyridinyl]-4-chloro- (CA INDEX NAME)



RN 654056-40-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[3-[(3-aminopropyl)methylamino]propyl]amino]-N-[6-(2-benzofuranyl)-3-pyridinyl]- (CA INDEX NAME)



RN 654056-41-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2-aminoethyl)amino]-N-[6-(2-benzofuranyl)-3-pyridinyl]- (CA INDEX NAME)



RN 654056-47-0 CAPLUS
CN 3-Isothiazolecarboxamide, N-(4-benzo[b]thien-2-ylphenyl)-4-chloro-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-48-1 CAPLUS
CN 3-Isothiazolecarboxamide, N-(4-benzo[b]thien-2-ylphenyl)-4-chloro-5-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-49-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-benzo[b]thien-2-ylphenyl)-2-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-50-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-benzo[b]thien-2-ylphenyl)-2-[[2-(1-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-51-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-benzo[b]thien-2-ylphenyl)-2-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-52-7 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[[3-[(3-aminopropyl)methylamino]propyl]amino]-4-chloro-N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (CA INDEX NAME)



RN 654056-53-8 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(2-aminoethyl)amino]-4-chloro-N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (CA INDEX NAME)



RN 654056-54-9 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(3-aminopropyl)amino]-4-chloro-N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (CA INDEX NAME)



RN 654056-55-0 CAPLUS
CN 3-Isothiazolecarboxamide, 4-chloro-5-[[3-(dimethylamino)propyl]amino]-N-[4-(6-methyl-2-benzothiazolyl)phenyl]- (CA INDEX NAME)



RN 654056-56-1 CAPLUS
CN 3-Isothiazolecarboxamide, 4-chloro-5-[[3-(dimethylamino)propyl]amino]-N-[4-(5-methylfuro[3,2-b]pyridin-2-yl)phenyl]- (CA INDEX NAME)



RN 654056-57-2 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(2-aminoethyl)amino]-4-chloro-N-[4-(1H-indol-2-yl)phenyl]- (CA INDEX NAME)



RN 654056-58-3 CAPLUS
CN 3-Isothiazolecarboxamide, 4-chloro-5-[[3-(dimethylamino)propyl]amino]-N-[4-(1H-indol-2-yl)phenyl]- (CA INDEX NAME)



RN 654056-59-4 CAPLUS
CN 3-Isothiazolecarboxamide, 4-chloro-N-[4-(1H-indol-2-yl)phenyl]-5-[[2-(1-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-60-7 CAPLUS
CN 3-Isothiazolecarboxamide, 4-chloro-N-[4-(1H-indol-2-yl)phenyl]-5-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-61-8 CAPLUS
CN 3-Isothiazolecarboxamide, 4-chloro-N-[4-(1H-indol-2-yl)phenyl]-5-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-62-9 CAPLUS
CN 3-Isothiazolecarboxamide, 4-chloro-N-[4-(1H-indol-2-yl)phenyl]-5-[[2-(4-methyl-1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-63-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(2-aminoethyl)amino]-N-[4-(1H-indol-2-yl)phenyl]- (CA INDEX NAME)



RN 654056-64-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[3-(dimethylamino)propyl]amino]-N-[4-(1H-indol-2-yl)phenyl]- (CA INDEX NAME)



RN 654056-65-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1H-indol-2-yl)phenyl]-2-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-66-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1H-indol-2-yl)phenyl]-2-[[2-(4-methyl-1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-67-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1H-indol-2-yl)phenyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-68-5 CAPLUS
CN 3-Isothiazolecarboxamide, N-(6-benzo[b]thien-2-yl-3-pyridinyl)-4-chloro-5-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-69-6 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[(4-aminobutyl)amino]-N-(6-benzo[b]thien-2-yl-3-pyridinyl)-4-chloro- (CA INDEX NAME)



RN 654056-70-9 CAPLUS
CN 3-Isothiazolecarboxamide, N-(6-benzo[b]thien-2-yl-3-pyridinyl)-4-chloro-5-[[2-(1-piperidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-71-0 CAPLUS
CN 3-Isothiazolecarboxamide, N-(6-benzo[b]thien-2-yl-3-pyridinyl)-4-chloro-5-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-72-1 CAPLUS
CN 3-Isothiazolecarboxamide, 5-[[3-[(3-aminopropyl)methylamino]propyl]amino]-N-(6-benzo[b]thien-2-yl-3-pyridinyl)-4-chloro- (CA INDEX NAME)



RN 654056-73-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-benzo[b]thien-2-yl-3-pyridinyl)-2-[[2-(1-piperidinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-74-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-benzo[b]thien-2-yl-3-pyridinyl)-2-[[2-(1-piperazinyl)ethyl]amino]- (CA INDEX NAME)



RN 654056-75-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-benzo[b]thien-2-yl-3-pyridinyl)-2-[[3-(dimethylamino)propyl]amino]- (CA INDEX NAME)



RN 654056-76-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-aminobutyl)amino]-N-(6-benzo[b]thien-2-yl-3-

pyridinyl)- (CA INDEX NAME)



RN 654056-77-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[3-[(3-aminopropyl)methylamino]propyl]amino]-N-(6-benzo[b]thien-2-yl-3-pyridinyl)- (CA INDEX NAME)



L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:356439 CAPLUS
DOCUMENT NUMBER: 138:368779
TITLE: Preparation of isoquinolines as 5-HT antagonists for treatment of psychiatric disorders
INVENTOR(S): Angst, Christof; Haeberlein, Markus; Hill, Daniel; Jacobs, Robert; Moore, Gary; Pierson, Edward; Shenvi, Ashokkumar Bhikkappa
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037887	A1	20030508	WO 2002-SE1988	20021101
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2464342	A1	20030508	CA 2002-2464342	20021101
AU 2002343313	A1	20030512	AU 2002-343313	20021101
EP 1451172	A1	20040901	EP 2002-780244	20021101

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002013778	A	20041109	BR 2002-13778		20021101
CN 1608061	A	20050420	CN 2002-826281		20021101
JP 2005516896	T	20050609	JP 2003-540168		20021101
HU 2005001089	A2	20070928	HU 2005-1089		20021101
IN 2004DN01022	A	20070302	IN 2004-DN1022		20040419
MX 2004PA04076	A	20040723	MX 2004-PA4076		20040429
ZA 2004003240	A	20050407	ZA 2004-3240		20040429
US 20070010526	A1	20070111	US 2004-494424		20040430
NO 2004002154	A	20040729	NO 2004-2154		20040525
PRIORITY APPLN. INFO.:			SE 2001-3644	A	20011101
			WO 2002-SE1988	W	20021101

OTHER SOURCE(S): MARPAT 138:368779

GI



I



II

AB Title compds. I [wherein W = CO, CONRa, NRaCO, CO(CH2)nNRaCO, CSNRa, COCH2O, SO2NRa, NRaSO2, CH2NRa, COCH2, CH2CO, or 5-membered heterocyclyl; X = (un)substituted aryl or heterocyclyl; Y = bond, CH2, O, S, SO, CO, SO2, NRb, or NRbSO2; Z = Rb, CO2Ra, CON(Ra)2, NHRb, alkyl-N(Ra)2, SO2Rc, or (un)substituted aryl(alkyl) or heterocyclyl; R1 = halo, alkyl, ORa, SOpRa, N(Ra)2, or CN; R2 = aryl or heterocyclyl(carbonyl); Ra = H or (un)substituted alkyl; Rb = H, alkyl(sulfanyl), alkanoyl, aryl(alkyl), or arylalkoxyalkyl; Rc = alkyl, aryl, or heterocyclyl; m = 0 or 1; n = 0-4; p = 0-2;] were prepared as 5-HT1B and 5-HT1D antagonists (no data). For example, O-methylation of 5-hydroxyisoquinoline using NaOBu-t and PhMe3NCl in DMF (85%), followed by bromination with bromine in AcOH gave 5-methoxy-8-bromoisoquinoline (47%). Substitution with N-methylpiperazine using NaOBu-t, BINAP, and tris(dibenzylideneacetone)dipalladium in PhMe and subsequent reduction with NaCNBH3 and BF3•Et2O in MeOH gave 5-methoxy-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline. Coupling of 4-(bromomethyl)phenylacetic acid with morpholine in the

presence of K2CO3 in MeCN provided 4-(morpholinomethyl)phenylacetic acid. Amidation of the tetrahydroisoquinoline with the phenylacetic acid in DMF afforded II. I are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders (no data). The compds. may also be useful in the treatment of gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm, and sexual dysfunction (no data).

IT 521315-36-6P, 5-Methoxy-8-(4-methylpiperazin-1-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid [4-(6-methylbenzothiazol-2-yl)phenyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-HT antagonist; preparation of isoquinolines as 5-HT1B and 5-HT1D antagonists for treatment of psychiatric disorders)

RN 521315-36-6 CAPLUS

CN 2(1H)-Isoquinolinecarboxamide, 3,4-dihydro-5-methoxy-N-[4-(6-methyl-2-benzothiazolyl)phenyl]-8-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:275753 CAPLUS
DOCUMENT NUMBER: 136:309843
TITLE: Preparation of thiophenes as phosphate transport inhibitors
INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028353	A2	20020411	WO 2001-US31318	20011005
WO 2002028353	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002013048 A5 20020415 AU 2002-13048 20011005
PRIORITY APPLN. INFO.: US 2000-238068P P 20001005
WO 2001-US31318 W 20011005

OTHER SOURCE(S): MARPAT 136:309843
GI



I



II



III

AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

IT 409362-41-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenes as phosphate transport inhibitors)

RN 409362-41-0 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (CA INDEX NAME)



L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:496928 CAPLUS
DOCUMENT NUMBER: 111:96928
ORIGINAL REFERENCE NO.: 111:16296h,16297a
TITLE: Synthesis of actinomycin analogs. XVII. Actinomycin amides containing a benzimidazole fragment
AUTHOR(S): Sklyarova, I. V.; Kuznetsov, V. A.; Garabadzhiu, A. V.; Glibin, E. N.; Ginzburg, O. F.
CORPORATE SOURCE: Leningr. Tekhnol. Inst., Leningrad, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1989), 25(1), 186-9
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 111:96928
GI



AB Interaction of 4,3,2-R(PhCH2O)(O2N)C6H4COCl (R = H, Me) with benzimidazole derivs. R1H (R1 = R2, R3) gave the resp. acylamino derivs., which were cyclized to phenoxazinones I (R = H, Me, R1 = R2; R = Me, R1 = R3) via hydrogenation and oxidation I were used in the preparation of polyfunctional DNA,
in which actinocin, the chromophore of actinomycin, combines with

benzimidazole-cintg. groups.

IT 122183-12-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 122183-12-4 CAPLUS

CN 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis[4-[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1H-benzimidazol-2-yl]phenyl]-4,6-dimethyl-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NMe2

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:524074 CAPLUS
DOCUMENT NUMBER: 99:124074
ORIGINAL REFERENCE NO.: 99:19117a,19120a
TITLE: Azo dyes and their metal complexes
INVENTOR(S): Puentener, Alois
PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Switz.
SOURCE: Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 79858	A1	19830525	EP 1982-810480	19821110
EP 79858	B1	19851227		
R: CH, DE, FR, GB, LI				
US 4625017	A	19861125	US 1982-441125	19821112
JP 58089657	A	19830528	JP 1982-199835	19821116
JP 59045699	B	19841108		

PRIORITY APPLN. INFO.: CH 1981-7353 A 19811116
OTHER SOURCE(S): MARPAT 99:124074
GI



I



II

AB Dyes with general structure I are prepared, where R represents the residue of a benzene- or naphthalene-type diazo component with a metalizable OH group ortho to the azo group, R1 = Me, ClCH2, or C1-4 alkyl-, C1-4 alkoxy-, or halo-substituted Ph, R2 = H or C1-4 alkyl, R3 = H or Me, n = 0 or 1, and m = 0, 1, 2, or 3. Heavy metal complexes (Cu, Co, Cr, etc.) of I are yellow, orange-red to brown or olive dyes, e.g. for cotton, leather, paper, or polyamide. Thus, diazotization of 2,4-H2N(H2NSO2)C6H3OH [98-32-8] and coupling with 6-methyl-2-[p-(acetoacetylamino)phenyl]benzothiazole-7-sulfonic acid [5855-96-9] gave II [87074-85-9], which was applied to cotton and treated with CuSO4 to form the 1:1 Cu complex [87067-62-7], a fast yellow dye.

IT 87134-07-4
RL: USES (Uses)
(dye, for leather)

RN 87134-07-4 CAPLUS

CN Chromate(4-), [3-hydroxy-4-[(2-hydroxy-1-naphthalenyl)azo]-7-nitro-1-naphthalenesulfonato(3-)][2-[4-[[2-[(2-hydroxy-3-nitro-5-sulfophenyl)azo]-1,3-dioxobutyl]amino]phenyl]-6-methyl-7-benzothiazolesulfonato(4-)]-, tetrahydrogen (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



PAGE 3-A



●4 H^+

IT 87140-42-9P
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(manufacture of, as dye for leather)
RN 87140-42-9 CAPLUS
CN Chromate(4-), [3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-2-hydroxy-5-nitrobenzenesulfonato(3-)][2-[4-[[2-[(2-hydroxy-3-nitro-5-sulfophenyl)azo]-1,3-dioxobutyl]amino]phenyl]-6-methyl-7-benzothiazolesulfonato(4-)]-, tetrasodium (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 4 Na^+

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	50.01	229.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

STN INTERNATIONAL LOGOFF AT 15:18:45 ON 04 SEP 2008